Avacta Group Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVCT.L research report →
Companywww.avacta.com
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays.
- CEO
- Christina Marie Coughlin
- IPO
- 2003
- Employees
- 154
- HQ
- Wetherby, GB
Price Chart
Valuation
- Market Cap
- $341.61M
- P/E
- -17.49
- P/S
- 6100.25
- P/B
- 2067.72
- EV/EBITDA
- -29.05
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1217.86%
- Op Margin
- -23378.57%
- Net Margin
- -30398.21%
- ROE
- -361.23%
- ROIC
- -63.08%
Growth & Income
- Revenue
- $113.00K · -96.04%
- Net Income
- $-52,841,000 · -111.81%
- EPS
- $-0.16 · -74.86%
- Op Income
- $-32,558,000
- FCF YoY
- -48.36%
Performance & Tape
- 52W High
- $92.00
- 52W Low
- $26.00
- 50D MA
- $73.46
- 200D MA
- $65.49
- Beta
- -0.10
- Avg Volume
- 2.28M
Get TickerSpark's AI analysis on AVCT.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AVCT.L Coverage
We haven't published any research on AVCT.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AVCT.L Report →